Piramal Pharma Beats Revenue and EBITDA Estimates in 2QFY27
Motilal Oswal says Piramal Pharma's 2QFY27 revenue and EBITDA beat expectations by 11% and 56%, respectively. The company reported PAT of INR50 million versus an expected loss of INR684 million.
Motilal Oswal's research report on Piramal PharmaPiramal Pharma (PIRPHARM) delivered better-than-expected financial performance, with an 11%/56% beat on revenue/EBITDA in 2QFY27. It also delivered a PAT of INR50m vs. expectation of a loss of INR684m for 2Q. Robust traction in CDMO and complex hospi…